Literature DB >> 8387097

Cyclosporin H is a potent and selective formyl peptide receptor antagonist. Comparison with N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L- leucyl-L-phenylalanine and cyclosporins A, B, C, D, and E.

K Wenzel-Seifert1, R Seifert.   

Abstract

The cyclic undecapeptide, cyclosporin (Cs) H, is a potent inhibitor of FMLP-induced superoxide anion (O2-) formation in human neutrophils. We studied the effects of CsH in comparison with those of N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L- phenylalanine (BocPLPLP), a well known formyl peptide receptor antagonist, and of other Cs on activation of N6,2'-O-dibutyryl adenosine 3:5'-monophosphate-differentiated HL-60 cells and human erythroleukemia cells (HEL cells). CsH inhibited FMLP binding in HL-60 membranes with a Ki (inhibition constant) of 0.10 microM. CsH inhibited activation by FMLP of high affinity GTPase (the enzymatic activity of alpha-subunits of heterotrimeric regulatory guanine nucleotide-binding proteins) in HL-60 membranes with a Ki of 0.79 microM. CsH inhibited the stimulatory effects of FMLP on cytosolic Ca2+ concentration ([Ca2+]i), O2- formation, and beta-glucuronidase release with Ki values of 0.08, 0.24, and 0.45 microM, respectively. BocPLPLP was 14-fold less potent than CsH in inhibiting FMLP binding and 4- to 6-fold less potent than CsH in inhibiting FMLP-induced GTP hydrolysis, rises in [Ca2+]i, O2- formation, and beta-glucuronidase release. CsA reduced FMLP-induced O2- formation by 20%, but CsB, CsC, CsD, and CsE did not. CsA, CsB, CsC, CsD, and CsE did not affect FMLP-induced rises in [Ca2+]i. BocPLPLP inhibited leukotriene B4-induced rises in [Ca2+]i with a Ki of 0.33 microM, whereas CsH showed no inhibitory effect. CsH and BocPLPLP did not inhibit the rises in [Ca2+]i induced by several other stimuli in HL-60 cells and HEL cells. Our results show that 1) CsH is a more potent formyl peptide receptor antagonist than BocPLPLP; 2) unlike BocPLPLP, CsH is selective; and 3) N-methyl-D-valine which is present at position 11 of the amino acid sequence of CsH but not of other Cs is crucial for FMLP antagonism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387097

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Functional differences between human formyl peptide receptor isoforms 26, 98, and G6.

Authors:  Katharina Wenzel-Seifert; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-05       Impact factor: 3.000

2.  Human neutrophil formyl peptide receptor phosphorylation and the mucosal inflammatory response.

Authors:  Giovanna Leoni; Jeannie Gripentrog; Connie Lord; Marcia Riesselman; Ronen Sumagin; Charles A Parkos; Asma Nusrat; Algirdas J Jesaitis
Journal:  J Leukoc Biol       Date:  2014-11-13       Impact factor: 4.962

3.  Circulating mitochondrial DAMPs cause inflammatory responses to injury.

Authors:  Qin Zhang; Mustafa Raoof; Yu Chen; Yuka Sumi; Tolga Sursal; Wolfgang Junger; Karim Brohi; Kiyoshi Itagaki; Carl J Hauser
Journal:  Nature       Date:  2010-03-04       Impact factor: 49.962

4.  Circulating mitochondria in deceased organ donors are associated with immune activation and early allograft dysfunction.

Authors:  Justin Pollara; R Whitney Edwards; Liwen Lin; Victoria A Bendersky; Todd V Brennan
Journal:  JCI Insight       Date:  2018-08-09

5.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 6.  Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Liliya N Kirpotina; Mark T Quinn
Journal:  Int Immunopharmacol       Date:  2015-09-15       Impact factor: 4.932

7.  Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair.

Authors:  Giovanna Leoni; Ashfaqul Alam; Philipp-Alexander Neumann; J David Lambeth; Guangjie Cheng; James McCoy; Roland S Hilgarth; Kousik Kundu; Niren Murthy; Dennis Kusters; Chris Reutelingsperger; Mauro Perretti; Charles A Parkos; Andrew S Neish; Asma Nusrat
Journal:  J Clin Invest       Date:  2012-12-17       Impact factor: 14.808

8.  The G-protein-coupled formylpeptide receptor FPR confers a more invasive phenotype on human glioblastoma cells.

Authors:  J Huang; K Chen; J Chen; W Gong; N M Dunlop; O M Z Howard; Y Gao; X-w Bian; J M Wang
Journal:  Br J Cancer       Date:  2010-03-02       Impact factor: 7.640

Review 9.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

10.  Mycobacteria attenuate nociceptive responses by formyl peptide receptor triggered opioid peptide release from neutrophils.

Authors:  Heike L Rittner; Dagmar Hackel; Philipp Voigt; Shaaban Mousa; Andrea Stolz; Dominika Labuz; Michael Schäfer; Michael Schaefer; Christoph Stein; Alexander Brack
Journal:  PLoS Pathog       Date:  2009-04-03       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.